KLRS
Kalaris Therapeutics, Inc.
Healthcare — Biotechnology
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Price History
Fundamentals
| Market Cap | $107.78M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.79 |
| EPS (TTM) | $-0.79 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -66.60% |
| Debt/Equity | 2.06 |
| Recommendation | Strong Buy 1.5 |
| Analyst Target | $18.71 |
| Analysts | 7 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 59.1 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $11.88 |
| 52-Week Low | $2.14 |
| 50-Day Avg | $4.92 |
| 200-Day Avg | $6.68 |
| Avg Volume | 90.1K |
| Volume | 54.3K |
Performance Analysis
BULLISHKLRS shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:17 UTC
Back to Screener Export Report